BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2

The BRCA Challenge is a long-term data-sharing project initiated within the Global Alliance for Genomics and Health (GA4GH) to aggregate BRCA1 and BRCA2 data to support highly collaborative research activities. Its goal is to generate an informed and current understanding of the impact of genetic variation on cancer risk across the iconic cancer predisposition genes, BRCA1 and BRCA2. Initially, reported variants in BRCA1 and BRCA2 available from public databases were integrated into a single, newly created site, www.brcaexchange.org. The purpose of the BRCA Exchange is to provide the community with a reliable and easily accessible record of variants interpreted for a high-penetrance phenotype. More than 20,000 variants have been aggregated, three times the number found in the next-largest public database at the project's outset, of which approximately 7,250 have expert classifications. The data set is based on shared information from existing clinical databases-Breast Cancer Information Core (BIC), ClinVar, and the Leiden Open Variation Database (LOVD)-as well as population databases, all linked to a single point of access. The BRCA Challenge has brought together the existing international Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium expert panel, along with expert clinicians, diagnosticians, researchers, and database providers, all with a common goal of advancing our understanding of BRCA1 and BRCA2 variation. Ongoing work includes direct contact with national centers with access to BRCA1 and BRCA2 diagnostic data to encourage data sharing, development of methods suitable for extraction of genetic variation at the level of individual laboratory reports, and engagement with participant communities to enable a more comprehensive understanding of the clinical significance of genetic variation in BRCA1 and BRCA2.

[1]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[2]  P. Broca.  Traité des tumeurs , 1866 .

[3]  Daniel G. MacArthur,et al.  The ExAC browser: displaying reference data information from over 60 000 exomes , 2016, bioRxiv.

[4]  J. Garber,et al.  Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care , 2016, Breast Cancer Research and Treatment.

[5]  F. Couch,et al.  BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk , 2012, Journal of Medical Genetics.

[6]  F. Couch,et al.  BRCA 1 R 1699 Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk , 2012 .

[7]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[8]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[9]  Vincent A. Fusaro,et al.  A Python package for parsing, validating, mapping and formatting sequence variants using HGVS nomenclature , 2014, Bioinform..

[10]  A. Zharkikh,et al.  Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation , 2004, Journal of Medical Genetics.

[11]  Alun Thomas,et al.  Classification of rare missense substitutions, using risk surfaces, with genetic‐ and molecular‐epidemiology applications , 2008, Human mutation.

[12]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[13]  M. Watson,et al.  The Human Variome Project , 2016, Human mutation.

[14]  A. Spurdle,et al.  The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium , 2017, Journal of Medical Genetics.

[15]  R. Leinonen,et al.  The 1000 Genomes Project: data management and community access , 2012, Nature Methods.

[16]  Christophe Béroud,et al.  BRCA Share: A Collection of Clinical BRCA Gene Variants , 2016, Human mutation.

[17]  F. Couch,et al.  Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes , 2017, Annals of Surgical Oncology.

[18]  Nasim Vasli,et al.  Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR) , 2017, Genetics in Medicine.

[19]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[20]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[21]  C. Coutant,et al.  The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? , 2016, Oncotarget.

[22]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[23]  Fergus J Couch,et al.  Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance , 2016, npj Genomic Medicine.

[24]  Fergus J Couch,et al.  A review of a multifactorial probability‐based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) , 2012, Human mutation.

[25]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[26]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[27]  F. Couch,et al.  Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs , 2012, Human mutation.

[28]  Dong Liang,et al.  BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. , 2016, Journal of the National Cancer Institute.

[29]  Csilla Szabo,et al.  The Breast Cancer Information Core: Database design, structure, and scope , 2000, Human mutation.

[30]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[31]  K. Offit,et al.  Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Eloisa Arbustini,et al.  RE: BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. , 2016, Journal of the National Cancer Institute.

[33]  K. Offit.  Multigene Testing for Hereditary Cancer: When, Why, and How. , 2017, The Journal of the National Comprehensive Cancer Network.

[34]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[35]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[36]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[37]  Jacob A. Tennessen,et al.  Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.

[38]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[39]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[40]  W. Klein,et al.  Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance , 2017, Journal of Genetic Counseling.

[41]  S. Cross,et al.  BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. , 2017, Cancer research.

[42]  Jing Wang,et al.  CrossMap: a versatile tool for coordinate conversion between genome assemblies , 2014, Bioinform..

[43]  Annette Lee,et al.  Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations , 2018, Human mutation.

[44]  Robert Cook-Deegan,et al.  Public variant databases: liability? , 2016, Genetics in Medicine.

[45]  R. Jagsi,et al.  Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[47]  D. Nix,et al.  Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants , 2016, Human mutation.